Who is a Candidate for Immunotherapy? Understanding PD‐L1, Microsatellite Instability, Tumor Mutation Burden, and Deficient Mismatch Repair
Who is a Candidate for Immunotherapy? Understanding PD?L1, Microsatellite Instability, Tumor Mutation Burden, and Deficient Mismatch Repair is organized by Prime Education, LLC.
Release Date: May 3, 2023
Expiration Date: May 2, 2024
Description:
The advent of immunotherapy in cancer treatment has led to remarkable and durable benefits for many patients with solid tumors. However, with new approvals, indications, and differing eligibility criteria dependent on tumor type, it can be challenging to know which patients may benefit from immunotherapy. Join us for the latest video activity in our Precision Oncology Accelerator Hub for expert discussion on identifying patients who are eligible for immunotherapy based on tumor type, stage, and biomarkers such as PD-L1, microsatellite instability, tumor mutation burden, and deficient mismatch repair.
Agenda:
• Overview of Evidence-Based Practices for Using PD-L1, Microsatellite Instability, Tumor Mutation Burden, and Deficient Mismatch Repair to Identify Candidates for Immunotherapy
• Immunotherapy Indications Based on Tumor Type, Stage, and Biomarker Status
Learning Objectives:
• Identify frequent biomarkers across solid tumors and understand appropriate timing of testing to detect these biomarkers
• Interpret results of next-generation sequencing and other testing methodologies to identify biomarkers predictive of response to immunotherapies and targeted therapies.